More About Jorge
Jorge Conde is a General Partner on the Bio + Health team, where he focuses on life sciences and healthcare investments across therapeutics, diagnostics, tools, and software. Jorge currently serves on the boards of Asimov, CAMP4, Cartography, Doppler Bio, Dyno, Earli, IDRx, Komodo Health, Octant Bio, Tome Biosciences, and Vicinitas.
Prior to joining Andreessen Horowitz, Jorge served as Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer for Syros. Jorge was also cofounder and Chief Executive Officer of Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Before that, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.
Jorge holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in biology from Johns Hopkins University. Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He previously served on the board of the Museum of Science, Boston.
Born and raised in Miami by Cuban and Peruvian parents, and married to a Madrileña, Jorge and his family of six live in California. The family cheers for Real Madrid, the Boston Red Sox, and the Miami Dolphins.
Latest Content
-
In this episode, a16z partners Jorge Conde and Jay Rughani sit down with Sajith Wickramasekara, CEO and cofounder of Benchling, to unpack the evolution of Benchling from idea to transformative software platform.
-
Jonathan Lim, chairman and CEO of Erasca, joins Jorge Conde, general partner at a16z. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making.
-
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z. This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI.
-
Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health.
-
John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joins Jorge Conde, general partner at a16z Bio + Health.
-
Today's episode features the cofounders of Tome Biosciences, Rahul Kakkar, CEO of Tome, and John Finn, CSO. They are joined by Jorge Conde, general partner at a16z Bio + Health.
-
All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.
-
Tome is launching with over $200 million to advance its PGI platform to focus on in vivo and ex vivo applications, with support from a16z Bio + Health, ARCH, GV, Longwood, Polaris and other leading investors. First up on Tome’s in vivo surgical slate: monogenic diseases of the liver. On the ex vivo cell engineering front, Tome is using PGI to rewire cells to cure common, chronic diseases—an area of great promise—with an initial focus on B-cell driven autoimmune diseases.
-
Smart energy grids. Voice-first companion apps. Programmable medicines. AI tools for kids. We asked over 40 partners across a16z to preview one big idea they believe will drive innovation in 2024. Here in our 3-part series, you’ll hear directly from partners across all our verticals, as we dive even more deeply into these ideas. What’s the why now? Who is already building in these spaces? What opportunities and challenges are on the horizon? And how can you get involved?
-
Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ EXA-cell, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases.
-
Each new modality needs to find its platform-disease fit—the diseases it is uniquely suited for. But finding fit has increasingly turned into a fight; many have crowded into the same indications. With an expanding arsenal to treat disease, how will patients, clinicians, and the market determine what tool to use?
-
Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.
-
In this episode, Dan joins general partner Jorge Conde and investment partner Becky Pferdehirt to discuss how he got started working in chemical biology and chemoproteomics and his experience founding companies, along with leading lab and pharma collaborations.
-
In this exclusive conversation from the Bio + Health BUILD summit, founding partner Ben Horowitz sits down with general partner Jorge Conde.
-
In this exclusive conversation from a16z’s Bio and Health BUILD Summit, founding partner Ben Horowitz sits down with general partner Jorge Conde. They discuss everything from the inspiration behind Ben’s book The Hard Thing About Hard Things, how the open Internet was secured, the difference between wartime and peacetime CEOs, scaling culture, and understanding how bio & healthcare differs from other forms of technology.
-
As we strive to find and support the most ambitious life sciences founders, we also work to connect these founders with exceptional advisors who have traveled the journey before.
-
Greg Verdine, PhD, is a leader in the discovery, development, and commercialization of new drug modalities, a repeat founder, and the newest venture partner at a16z Bio + Health. He is joined by Vineeta Agarwala and Jorge Conde, general partners at a16z Bio + Health.
-
Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde.
-
In this episode, Jorge Conde, general partner at a16z Bio + Health, talks with Josh Mandel-Brehm, founding CEO of CAMP4.
-
Longtime podcast showrunner (2014-2022), primary host, and editor Sonal Chokshi shares three best-of episodes as she shifts gears and the show goes on hiatus until relaunched with a new host.
-
The biotech industry’s appetite for science-native SaaS tools is accelerating and will modernize how medicines are discovered, developed, and distributed.
-
Kevin Parker, cofounder and CEO of Cartography Biosciences, joins Jorge Conde, general partner at a16z Bio + Health, and Olivia Webb, editorial lead.
-
HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cocktail therapies combine multiple drugs: Some hit parts of the replication machinery the virus uses to make copies of itself...
-
Vicinitas (noun), Latin
-
“Maps are the most condensed humanized spaces of all...They make the landscape fit indoors, make us masters of sights we can't see and spaces we can't cover.” -- Robert Harbison, Professor of Architecture
-
Rick Young is a professor of biology at MIT who studies RNA that is transcribed from the part of the genome that does not code for proteins, known as non-coding DNA. This part of the genome was once referred to as ‘junk...
-
Biotech founders face a variety of challenges in building a successful startup. Beyond confronting daunting scientific and technical hurdles, they must develop a strategy to ensure their technology has a compelling business model and is focused on the right problems. Also, they need a plan for how the tech will go the distance — i.e., when to go it alone or seek to partner.
-
2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both...
-
As new biological technologies shift the way we make new medicines — from “bespoke craftsmanship to industrialized drug development” — we are seeing bio platforms truly deliver a dizzying array of novel discoveries, tool...
-
On this episode, we are taking a pulse-check on the state of the intersection between biology, healthcare, and technology with two scientists that sit at another intersection, that of academia and industry: Alexander Mar...
-
In today’s episode we have two short segments, both on bioscience topics.
-
Given recent news of drug company settlements, policy moves, and more, this episode is a rerun of one of our early explainers on the opioid crisis -- how do opioids work; who's to blame; and where does (and doesn't) tech come in?
-
"Using AI to design a fleet of AAV delivery vehicles to create the FedEx for gene therapy."
-
Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the news that came out a week ago that a candidate "malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal”. While the findings are still in preprint with The Lancet, the resulting buzz and phrases quoted included everything from “unprecedented”, “groundbreaking work”, and “very exciting” to “high expectations”, “highly effective”, and “a hugely significant extra weapon”... A "weapon" in the war against malaria that is -- a disease that is estimated to cause over 400,000 deaths each year globally, and predominantly in children under the age of five.
-
We have two brief segments in today’s episode: News and analysis of the Johnson & Johnson COVID vaccine pause, and the widespread hack of Microsoft Exchange Servers across the country (and the dramatic and unusual steps the FBI took in response).
-
In today's episode of our news analysis show 16 Minutes, our topic is the ongoing buzz and the mixed news around the Johnson & Johnson vaccine, which was the third vaccine for COVID approved under Emergency Use Authorization by the FDA just a few weeks ago. Johnson & Johnson reported it as “the first single shot vaccine” and as having 85% efficacy in preventing severe disease across regions studied; meanwhile, STAT headlines reported 66% efficacy overall and 72% in the U.S. in preventing moderate to severe disease, calling it “a weapon but not a knockout punch.” And then we have various experts saying everything from “disappointing” to pointing out the dangers of comparing this vaccine to other vaccines such as Pfizer’s and Moderna’s, both of which we’ve talked about on this show. You can find all our ongoing vaccines coverage at a16z.com/vaccines.
-
In this episode, a16z General Partner Jorge Conde and Bio Eats World host Hanne Winarsky talk to Professor Rick Young, Professor of Biology and head of the Young Lab at MIT—all about "junk" DNA, or non-coding DNA.
-
Today we are revisiting a topic and episode that was originally aired back when Journal Club was part of the a16z podcast. We are covering it again in light of a new research article published in Science, as both this ep...
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.
-
Moderna CEO Stephane Bancel tells the story of not just the vaccine’s development, but the machine that made the vaccine: the platform, the technology, and the moves behind the vaccine’s development. Aired on Bio Eats World right after FDA EUA.
-
A year ago, none of us would believe that mRNA vaccines would be a household name. And yet here we are, at the end of 2020, counting the days towards a vaccine that could not just save lives but help bring us back into a...
-
Given our early and ongoing coverage of coronavirus in this feed, we share a recent episode of 16 Minutes breaking down the 4 D's and what to know about recent news around the vaccines.
-
In this episode of 16 Minutes with a16z bio general partners Vineeta Agarwala and Jorge Conde in conversation with Sonal Chokshi, we break it all down: the math, the science, and the practical considerations -- from "vaccine efficacy" vs. efficiency, from cold chains to distribution, from patients to the system... as well as from the past, to present future of, vaccines.
-
In this episode of Bio Eats World, a16z founder and internet pioneer Marc Andreessen and general partner Jorge Conde zoom out to discuss the large scale societal effects of the current pandemic on society, healthcare, bi...
-
The entire healthcare system is built around the idea that we can detect, diagnose, and manage disease effectively for patients. This pandemic has been a stress test of that capability, and we have roundly failed that te...
-
In this special episode of 16 Minutes, a16z general partners Vijay Pande and Jorge Conde, in conversation with Sonal Chokshi, examine the long arc and narrative of CRISPR, both backwards and forward; tease apart what's hype/ what's real in terms of where we really are, in practice; and... celebrate the incredible milestone this is. It's CRISPR!, and much more...
-
Over the past 15 years we have made huge advances in our ability to engineer the genome, meaning that we now have the ability to edit DNA in a programmable and precise manner. In the lab, these editing tools allow us to...
-
In this episode of Bio Eats World, we explore all the major revolutions in cancer treatment across the history of medicine—and what’s coming next. Hanne Winarsky delves into the past and future of the fight against cance...
-
WHEN are we going to have a COVID-19 vaccine, and how the heck are we going from 12 years of vaccine development compressed into 12 months or so? What will and won’t be compromised here, and where do new technologies (like mRNA) come in? Where will vaccines likely be distributed first; who will and won't get them initially; how do we maintain not just safety and efficacy of vaccines but trust and transparency when it comes to mis/information? We may actually see the emergence of a "Neo Anti-Vaxxer"... but we may also be entering a renaissance for vaccinology after this pandemic.
-
On this episode of the a16z Journal Club we discuss new research using engineered T cells to attack and destroy the "sleeping" cells that build up as we age and underlie many age-related conditions. This research lays the groundwork for a possible therapy that, in addition to treating specific diseases like liver fibrosis, is broadly health-promoting and restorative as we age.
-
Eroom’s Law is Moore’s Law spelled backwards. It’s a term that was coined in a Nature Reviews Drug Discovery article by researchers at Sanford Bernstein and describes the exponential decrease in biopharma research and de...
-
On this special holiday weekend edition of the a16z bio Journal Club we discuss a recent opinion article suggesting the end of Eroom’s Law—the decades long trend in biopharma R&D towards higher and higher costs per new drug—and our take on the big trends in this space.
Select Investments
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here: https://a16z.com/investment-list/.
